Grant: CIHR Fellowship
University of Toronto
$135,000.00
Mapping pathogenic chromatin complexes in advanced prostate cancer with ChemBioID
FY 2023-24
Summary
Prostate cancer is commonly treated with a therapy called androgen deprivation, which initially works by blocking a key protein molecule called the androgen receptor. However, many patients eventually become resistant to this treatment, leading to a more aggressive form of the cancer. As a CIHR fellow, I seek to uncover novel treatment strategies for this deadly disease. I will use a new technique called ChemBioID that uses innovative chemical biology and proteomics. It is unique because it detects proteins in their native environment. I will use ChemBioID to analyze the proteins that work with the androgen receptor in various types of prostate cancer cells. ChemBioID will be used to compare how the androgen receptor partner proteins change across different types and stages of the disease, including models of resistance to androgen deprivation. Informed by this, I will then target these partner proteins to stop the growth of prostate cancer cells. Ultimately, this research will reveal new ways to drug aggressive prostate cancer and could lead to more effective therapies and better outcomes for patients.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
493017
Name
Maitland Matthew E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Mapping pathogenic chromatin complexes in advanced prostate cancer with ChemBioID
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Androgen Receptor; Bioid; Bivalent Compounds; Chemical Biology; Chromatin Complexes; Epigenetics; Prostate Cancer; Protein Interactions; Proteomics; Therapy Resistance
Abstract
Prostate cancer is commonly treated with a therapy called androgen deprivation, which initially works by blocking a key protein molecule called the androgen receptor. However, many patients eventually become resistant to this treatment, leading to a more aggressive form of the cancer. As a CIHR fellow, I seek to uncover novel treatment strategies for this deadly disease. I will use a new technique called ChemBioID that uses innovative chemical biology and proteomics. It is unique because it detects proteins in their native environment. I will use ChemBioID to analyze the proteins that work with the androgen receptor in various types of prostate cancer cells. ChemBioID will be used to compare how the androgen receptor partner proteins change across different types and stages of the disease, including models of resistance to androgen deprivation. Informed by this, I will then target these partner proteins to stop the growth of prostate cancer cells. Ultimately, this research will reveal new ways to drug aggressive prostate cancer and could lead to more effective therapies and better outcomes for patients.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Maitland, Matthew E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~